Scynexis Inc stock is traded at $3.30, with a volume of 133,716. It is down -14.06% in the last 24 hours and down -34.39% over the past month. SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Previous Close:
$3.84
Open:
$3.67
24h Volume:
133,716
Relative Volume:
1.81
Market Cap:
$32.83M
Revenue:
$20.34M
Net Income/Loss:
-$24.52M
P/E Ratio:
-
EPS:
-$3.58
Net Cash Flow:
-$5.92M
1W Performance:
-14.51%
1M Performance:
-34.39%
6M Performance:
-56.25%
1Y Performance:
-34.63%
1-Day Range:
$3.28$3.72
1-Week Range:
$3.28$4.00
52-Week Range:
$3.28$9.12
Scynexis Inc Stock (SCYX) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS